Quality & complianceOfficial

Infarmed orders recall of Entecavir Viatris batches over active substance contamination concerns

🇵🇹 INFARMED · Thu 19 Nov 2026

Portugal's medicines authority has suspended distribution of affected batches after a partner regulator found manufacturing non-conformities at the active substance stage, citing potential contamination and cross-contamination.

Infarmed, the Portuguese medicines regulator, has ordered the recall of certain batches of Entecavir Viatris and the immediate suspension of their distribution. The instruction was issued on 19 November 2026 in Informative Circular No. 108/CD/550.20.001. Entecavir is an antiviral used to treat chronic hepatitis B.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Official source: INFARMED ↗

Article written by VigiEye from the official source (INFARMED). AI-assisted; check the source before acting.